Cell Source Stock-Based Compensation Growth & History (CLCS)

Cell Source's stock-based compensation was $288,424 for fiscal 2024.

View full Cell Source company overview

Cell Source annual stock-based compensation history

Cell Source annual stock-based compensation

Fiscal yearPeriod endedStock-based compensationChangeGrowth
20242024-12-31$288,424−$174,610−37.71%
20232023-12-31$463,034$385,147+494.49%
20222022-12-31$77,887−$341,514−81.43%
20212021-12-31$419,401−$372,267−47.02%
20202020-12-31$791,668−$52,460−6.21%
20192019-12-31$844,128$866,628
20182018-12-31−$22,500−$67,219
20172017-12-31$44,719−$70,040−61.03%
20162016-12-31$114,759−$21,125−15.55%
20152015-12-31$135,884−$765,416−84.92%
20142014-12-31$901,300$901,300
20132013-12-31$0

Cell Source stock-based compensation trends

Over the last five fiscal years, Cell Source's stock-based compensation decreased from $844,128 to $288,424, a change of −$555,704. The latest reported quarter, Q1 2025, shows $104,475.

About the metric

What stock-based compensation means

Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.

Calculation and source

SEC-reported stock-based compensation

TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Cell Source source filings ↗

Community posts

It’s quiet here.

No posts about CLCS yet. Start the conversation.

Write the first post